0.58% -0.065

Viatris Inc (VTRS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1118)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Nächster Verdiensttermin

Neueste SEC-Einreichungen

VTRS's Discussions on Twitter

Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VTRS Viatris Inc	13.73	15.89B	14.29B	-3.51B	1.85B	-2.9603
TAK Takeda Pharmaceutical Co Adr	17.82	56.14B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	114.58	48.74B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.03	44.85B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	28.67	34.12B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	540.33	23.35B	3.13B	1.27B	1.12B	26.39

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-09	Hochstufung	UBS	Neutral → Buy
2026-01-16	Hochstufung	Argus	Hold → Buy
2025-12-09	Eingeleitet	Barclays	Overweight
2025-10-15	Eingeleitet	Truist	Buy
2025-06-06	Eingeleitet	Goldman	Neutral
2024-07-19	Fortgesetzt	Jefferies	Buy
2023-10-23	Herabstufung	BofA Securities	Neutral → Underperform
2023-06-23	Herabstufung	Barclays	Equal Weight → Underweight
2023-04-24	Herabstufung	Barclays	Overweight → Equal Weight
2023-02-17	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Hochstufung	Jefferies	Hold → Buy
2022-11-10	Hochstufung	UBS	Sell → Neutral
2022-11-08	Hochstufung	Piper Sandler	Underweight → Neutral
2022-10-21	Fortgesetzt	Jefferies	Hold
2022-06-14	Eingeleitet	UBS	Sell
2022-05-10	Herabstufung	Piper Sandler	Neutral → Underweight
2022-03-01	Herabstufung	BofA Securities	Buy → Neutral
2022-03-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-06-15	Eingeleitet	Citigroup	Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2021-03-08	Herabstufung	Goldman	Buy → Neutral
2021-03-02	Herabstufung	JP Morgan	Overweight → Neutral
2021-02-26	Herabstufung	Wolfe Research	Outperform → Peer Perform
2021-01-05	Eingeleitet	Argus	Hold
2020-12-14	Eingeleitet	Bernstein	Mkt Perform

Alle ansehen

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Finanzdaten der Viatris Inc-Aktie (VTRS)

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst - TipRanks

Viatris resolves case over use of woman’s cancer cells (VTRS) - Seeking Alpha

Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research - Reuters

GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus

GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha

Viatris Collaborates With GoodRx for Discounts of Up to 85% on Medications - marketscreener.com

GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications - Business Wire

Trading Systems Reacting to (VTRS) Volatility - Stock Traders Daily

Propranolol Market Overall Study Report 2026-2033 | Teva - openPR.com

Viatris Stock Analysis: Strong 6-Month Gains vs. Poor 5-Year FundamentalsNews and Statistics - IndexBox

Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings? - Finviz

Viatris (VTRS): Should You Buy, Sell, or Hold After Q4 Results? - Bitget

Viatris Inc. (VTRS) provides updates on four recent regulatory milestones - MSN

Viatris Eyes Specialty Shift As FDA Reviews MR-141 Presbyopia Drug - Yahoo Finance

Viatris tops forecasts as earnings and revenue beat expectations - MSN

Goldman Sachs Adjusts Price Target on Viatris to $14 From $13, Maintains Neutral Rating - marketscreener.com

FDA Review Of MR-141 Puts Viatris Ophthalmic Growth Story In Focus - Sahm

Better Value & Growth: LLY, JNJ Top Viatris Stock - Trefis

Ex-Dividend Reminder: Alphabet, Constellation Energy and Viatris - Nasdaq

Viatris Stock Hits Day Low of $15.14 Amid Price Pressure - Markets Mojo

Viatris, Inc. Hits New 52-Week High at USD 16.46 - Markets Mojo

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq

Viatris Unit Can't Ax Patent For Anemia Drug Evrenzo - Law360

Generic Pharma Q4 2025 Earnings Review: Revenue Beat, Stock DeclineNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform

Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive - FinancialContent

VTRS Financials: Income Statement, Balance Sheet & Cash Flow | Viatris Inc Ord Shs - Stock Titan

A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review - simplywall.st

Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value - Finviz

Viatris Inc. stock rises Monday, outperforms market - MarketWatch

Viatris Inc. (VTRS) Stock Report: Navigating the Healthcare Giant’s 3.22% Dividend Yield and Revenue Growth - DirectorsTalk Interviews

Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4 - Finviz

Viatris Earnings Call Highlights Slow Growth, Cash Strength - TipRanks

UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve - Insider Monkey

UBS raises Viatris stock price target to $20 on cost savings - Investing.com India

Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media

UBS Adjusts Viatris Price Target to $20 From $18, Maintains Buy Rating - marketscreener.com

Viatris Inc. (NASDAQ:VTRS) Q4 2025 Earnings Call Transcript - Insider Monkey

Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date - Finviz

JPMorgan Adjusts Price Target on Viatris to $17 From $16, Maintains Neutral Rating - marketscreener.com

A Look At Viatris (VTRS) Valuation After Earnings Beat And 2026 Guidance Update - Yahoo Finance

Decoding Viatris Inc (VTRS): A Strategic SWOT Insight - GuruFocus

Viatris Earnings: Drugmaker Left 2025 With Momentum; 2026 to Bring Stability and Broad-Based Growth - Morningstar

Viatris: Q4 Earnings Snapshot - theheraldreview.com

BofA raises Viatris stock price target on cost-cutting plan - Investing.com

Viatris Inc. stock falls Thursday, underperforms market - MarketWatch

Is Strong Q4 Revenue And Steady Dividend Policy Altering The Investment Case For Viatris (VTRS)? - simplywall.st

Viatris Looks Well-Positioned for Durable Growth From New Launches and Cost Savings Initiatives - Morningstar

Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up - Finviz

Earnings call transcript: Viatris Q4 2025 earnings beat forecasts, stock up - Investing.com

Viatris Q4 2025 slides: earnings beat, major cost-cutting plan - Investing.com

Finanzdaten der Viatris Inc-Aktie (VTRS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie VTRS